254
Participants
Start Date
August 31, 2006
Primary Completion Date
January 31, 2008
Study Completion Date
January 31, 2008
PG-760564
100 mg BID, of oral PG-760564
Placebo dose
placebo, BID, oral for 12 weeks
PG-760564
25 mg BID, of oral PG-760564
Research Facility, Plainview
Research Facility, Erie
Research Facility, Duncansville
Research Facility, Charlotte
Research Facility, Wilmington
Research Facility, Decatur
Research Facility, Marietta
Research Facility, Rome
Research Facility, Chiefland
Research Facility, Tavares
Research Facility, Fort Lauderdale
Research Facility, Dunedin
Research Facility, Minot
Research Facility, Omaha
Research Facility, New Orleans
Research Facility, Hot Springs
Research Facility, Dallas
Research Facility, Dallas
Research Facility, San Antonio
Research Facility, Austin
Research Facility, Meridian
Research Facility, Beverly Hills
Research Facility, Mission Viejo
Research Facility, Elizabeth
Research Facility, Česká Lípa
Research Facility, Hustopeče
Research Facility, Prague
Research Facility, Uherské Hradiště
Research Facility, Zlín
Research Facility, Balatonfüred
Research Facility, Budapest
Research Facility, Eger
Research Facility, Győr
Research Facility, Gyula
Research Facility, Szolnok
Research Facility, Cambridge
Research Facility, The Hague
Research Facility, Częstochowa
Research Facility, Działdowo
Research Facility, Elblag
Research Facility, Gmina Końskie
Research Facility, Krakow
Research Facility, Krakow
Research Facility, Lublin
Research Facility, Poznan
Research Facility, Sopot
Research Facility, Szczecin
Research Facility, Torun
Research Facility, Warsaw
Research Facility, Lodz
Research Facility, Ashford
Research Facility, Glasgow
Research Facility, Liverpool
Procter and Gamble
INDUSTRY